Skip to content

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Drug Development · The big question

New Cell Model Helps Discover Drugs for Chemo Nerve Damage

A human iPSC-derived sensory neuron platform for high-throughput discovery of neuroprotectants against chemotherapy-induced peripheral neuropathy.

Editorial illustration for A human iPSC-derived sensory neuron platform for high-throughput discovery of neuroprotectants against chemotherapy-induced peripheral neuropathy.
Editorial illustration

Summary

Chemotherapy is a crucial treatment for cancer, but it frequently causes severe side effects. One of the most difficult is chemotherapy-induced peripheral neuropathy, a condition that damages the nerves and causes debilitating pain and numbness. Because scientists have lacked good laboratory models of human nerves, finding treatments to prevent this damage has been challenging. To solve this, researchers built a new testing platform using human induced pluripotent stem cells. These are regular adult cells that have been reprogrammed to grow into human sensory nerves. This gave the team a scalable and reliable way to study how paclitaxel, a common chemotherapy drug, causes nerve toxicity and damage.

With this new cellular testing ground, the research team went hunting for protective drugs. They rapidly screened a library of 192 compounds known as kinase inhibitors, which are drugs that block specific proteins involved in cell communication. Out of this batch, they identified 19 compounds that successfully shielded the nerves from chemotherapy damage. By genetically altering the cells, they discovered that protecting the nerves specifically required blocking a combination of three enzymes at the same time: MAP4K4, MINK1, and TNIK.

To confirm their findings, the researchers used targeted drugs to block those three specific enzymes. This approach successfully stopped nerve degeneration in their human cell models. Furthermore, the targeted treatment preserved nerve health and fiber density in a living mouse model experiencing chemotherapy-induced nerve damage.

Why it matters.

This research provides a powerful new tool for improving cancer care. Chemotherapy-induced peripheral neuropathy is a major dose-limiting side effect, meaning it can become so severe that doctors are forced to lower a patient's chemotherapy dose or stop the treatment altogether. By establishing a reliable human cell testing platform, the medical industry now has a clear path to discover and validate drugs that protect nerves. If successful, these protective treatments could dramatically improve the quality of life for cancer patients and potentially allow them to tolerate full doses of vital chemotherapy.

It is important to keep in mind that this research is currently in the early, preclinical stages. The findings rely exclusively on laboratory cell platforms and mouse models. Any potential treatments discovered using this system will require further validation and rigorous clinical trials to confirm whether they are safe and effective for human cancer patients. Nevertheless, this new platform marks a crucial step forward in addressing a widespread medical need.

From the source

The story in numbers.

Kinase inhibitors screened
192
Neuroprotective hits identified
19
Targeted STE20 kinases (MAP4K4, MINK1, TNIK)
3
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗